Why this US-listed medical stock is bucking the post-election trend
Brazilian medical education provider Afya is navigating a major domestic merger with Yduqs, which could reshape its Nasdaq listing and local market footprint.
American retail investors holding international equities in their brokerage accounts are used to navigating the complex world of American Depositary Receipts (ADRs), which often carry extra custody fees and tracking friction. However, a select group of foreign companies bypass this structure entirely by listing their primary shares directly on U.S. exchanges. One such company, the medical education provider Afya, has emerged as a rare bright spot for global investors looking for direct access to specialized emerging-market sectors.
On Friday, November 6, 2026, shares of Afya closed at $10.50, marking a 3.45% gain for the day. This upward movement came as the broader Brazilian market faced severe headwinds. The benchmark Bovespa index has dropped roughly 20% since the country’s recent presidential runoff, weighed down by fiscal concerns and a weakening Brazilian real. Despite this regional volatility, Afya has found support following a series of Wall Street updates and a massive pending domestic merger.
Headquartered in Nova Lima, Brazil, Afya is the country's leading medical education group. The company operates a highly defensive business model centered on undergraduate medical schools, residency preparation, and digital practice software for physicians. Because medical seats in Brazil are strictly regulated by the Ministry of Education, the supply of new doctors is limited, allowing Afya to maintain high tuition pricing power and near-100% occupancy rates.
The stock’s recent resilience is tied to a major corporate transformation. On September 23, 2026, Afya entered into a definitive merger agreement with Yduqs Participações S.A., another major Brazilian education player. The transaction, which is currently undergoing regulatory review by Brazil's antitrust authority, CADE, is projected to generate between BRL 2.0 billion and BRL 2.2 billion ($400 million) in net present value synergies. Under the terms of the agreement, the combined entity would delist Afya from the Nasdaq and consolidate its listing on Brazil's B3 exchange.
This pending deal has prompted major investment banks to adjust their outlooks. On November 3, 2026, JPMorgan Chase & Co. updated its assessment of the stock following the merger announcement. Meanwhile, Wall Street analysts on November 8, 2026, pointed to the company's robust cash generation. In its most recent financial disclosure, Afya reported a quarterly EPS of $0.43, beating analyst estimates of $0.40.
For foreign investors, the primary risk remains currency depreciation and the structural changes of the upcoming merger. If approved, the delisting will convert Nasdaq shares into Brazilian-listed equity, tying future returns directly to the performance of the local currency.
In your brokerage app
Afya Limited, which is listed directly on the Nasdaq under the ticker AFYA, can currently be traded like any domestic stock without ADR fees. For investors seeking diversified exposure, the company is also held in specialized emerging-market and small-cap exchange-traded funds, such as the Vanguard FTSE All-World ex-US Small-Cap ETF.
